Companies: 10,795·Total market cap: $144.5T
Exelixis, Inc.

Exelixis, Inc.

EXELNASDAQHealthcare● Active
$52.50
$-0.20(-0.38%)
Market Cap$13.2B
P/E Ratio—
52W High$52.98
52W Low$33.76
Cash on HandFinancialsRevenue

Exelixis, Inc. (EXEL) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

EXEL · cash on hand · updated Jan 2, 2026

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$1.06B▼ -4.7% vs prior year
FY · as of Jan 2, 2026 · Reported in USD
Cash & Cash Equiv. (CCE)
$482.5M
cashAndCashEquivalents
Short-Term Investments
$576.6M
shortTermInvestments
YoY Change vs Prior Year
-4.7%
vs prior fiscal year
Latest Quarter
$777.2M
Q2 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: January 2, 2026

Net cash vs debt

Cash & ST Investments$1.06BCash on Hand
Total Debt$173.0MTotal Debt
Net Cash / Net Debt+$886.1MNet Cash Position
Cash vs Debt Ratio
Cash 86%Debt 14%

Exelixis, Inc. has a net cash position of $886.1M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$1.06B − $173.0M = +$886.1M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
EXEL annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Jan 2, 2026Latest$1.06B-4.7%
Jan 3, 2025$1.11B+11.7%
Dec 31, 2023$995.3M-23.9%
Dec 31, 2022$1.31B-10.8%
Dec 31, 2021$1.47B+21.6%
EXEL cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.7%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Exelixis, Inc.
Exelixis, Inc.YOU
EXEL
$1.06B8.0%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Exelixis, Inc. (EXEL) cash on hand as of January 2, 2026 is $1.06B, comprising $482.5M in cash and cash equivalents (CCE) plus $576.6M in short-term investments — reported as Exelixis, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Exelixis, Inc. cash reserves or cash position.

Exelixis, Inc. annual cash on hand history shows decreased -4.7% in 2026: decreased -4.7% in 2026. Exelixis, Inc. cash reserves in 2026 reflect the company's capital allocation strategy.

Exelixis, Inc. carries total debt of $173.0M against cash of $1.06B, resulting in a net cash position of +$886.1M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

EXEL cash on hand · 5 questions

As of January 2, 2026, Exelixis, Inc. (EXEL) has $1.06B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $482,488,000 in cash and cash equivalents (CCE) plus $576,603,000 in short-term investments. Latest quarter (April 3, 2026): $777,207,000. Data sourced from the annual 10-K filing via FMP.

EXEL cash on handEXEL cash reservesEXEL cash 2026how much cash does EXEL have

▸ Source: FMP /balance-sheet-statement · US GAAP · Exelixis, Inc. · Exelixis, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: January 2, 2026